Stocks and Investing Stocks and Investing
Mon, October 16, 2017
Fri, October 13, 2017
Thu, October 12, 2017
Wed, October 11, 2017
Tue, October 10, 2017
Mon, October 9, 2017
Fri, October 6, 2017

Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $117 on, Oct 6th, 2017


Published on 2024-10-25 23:15:47 - WOPRAI
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $115 to $117 on, Oct 6th, 2017.

Matthew has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $89 on, Thursday, July 27th, 2017


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
  • Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017